Thromb Haemost 2019; 119(05): 726-734
DOI: 10.1055/s-0039-1678707
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Aspirin-Dependent Effects on Purinergic P2Y1 Receptor Expression

Isabella Massimi
1   Department of Experimental Medicine, ‘Sapienza’ University of Rome, Rome, Italy
,
Laura Alemanno
1   Department of Experimental Medicine, ‘Sapienza’ University of Rome, Rome, Italy
,
Maria Luisa Guarino
1   Department of Experimental Medicine, ‘Sapienza’ University of Rome, Rome, Italy
,
Raffaella Guerriero
2   Department of Cardiovascular, Dysmetabolic and Aging-associated Diseases, Istituto Superiore di Sanità, Rome, Italy
,
Massimo Mancone
3   Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, ‘Sapienza’ University of Rome, Rome, Italy
,
Andrea Ceccacci
3   Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, ‘Sapienza’ University of Rome, Rome, Italy
,
Luigi Frati
4   I.R.C.C.S Neuromed, Località Camerelle, Pozzilli (CB), Italy
,
Dominick J. Angiolillo
5   Division of Cardiology, University of Florida College of Medicine-Jacksonville, Florida, United States
,
Fabio M. Pulcinelli
1   Department of Experimental Medicine, ‘Sapienza’ University of Rome, Rome, Italy
› Author Affiliations
Funding This study was supported by a grant from ‘Sapienza’ - University of Rome 2015 to F.M.P.
Further Information

Publication History

23 July 2018

02 January 2019

Publication Date:
13 February 2019 (online)

Abstract

Chronic treatment with aspirin in healthy volunteers (HVs) is associated with recovery of adenosine diphosphate (ADP)-induced platelet activation. The purinergic P2Y1 receptor exerts its effects via a Gq-protein, which is the same biochemical pathway activated by thromboxane-A2 receptor. We hypothesized that recovery of ADP-induced platelet activation could be attributed to increased P2Y1 expression induced by chronic aspirin exposure. We performed a multi-phase investigation which embraced both in vitro and in vivo experiments conducted in (1) human megakaryoblastic DAMI cells, (2) human megakaryocytic progenitor cell cultures, (3) platelets obtained from HVs treated with aspirin and (4) platelets obtained from aspirin-treated patients. DAMI cells treated with aspirin or WY14643 (PPARα agonist) had a significant up-regulation of P2Y1 mRNA, which was shown to be a PPARα-dependent process. In human megakaryocytic progenitors, in the presence of aspirin or WY14643, P2Y1 mRNA expression was higher than in mock culture. P2Y1 expression increased in platelets obtained from HVs treated with aspirin for 8 weeks. Platelets obtained from patients who were on aspirin for more than 2 months had increased P2Y1 expression and ADP-induced aggregation compared with patients on aspirin treatment for less than a month. Overall, our results suggest that aspirin induces genomic changes in megakaryocytes leading to P2Y1 up-regulation and that PPARα is the nuclear receptor involved in this regulation. Since P2Y1 is coupled to the same Gq-protein of thromboxane-A2 receptor, platelet adaptation in response to pharmacological inhibition seems not to be receptor specific, but may involve other receptors with the same biochemical pathway.

Authors' Contributions

I.M. designed the study, performed experiments, analysed results and wrote the manuscript. L.A., M.L.G. and R.G. contributed to the performed experiment and analysed results. L.F. and D.J.A. contributed in the data interpretation and revision of the intellectual content of the manuscript. M.M. and A.C. contributed to the data collection and patient enrolment. F.M.P. provided the concept of the study, designed the study, analysed results, and wrote the manuscript.


 
  • References

  • 1 Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 2012; 72 (16) 2087-2116
  • 2 Angiolillo DJ, Cho JR. Aspirin treatment and outcomes in patients undergoing percutaneous coronary intervention: is there a role for pharmacodynamic testing?. J Am Coll Cardiol 2014; 64 (09) 872-874
  • 3 Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis. Int J Cardiol 2008; 128 (02) 166-171
  • 4 Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195-198
  • 5 Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167 (15) 1593-1599
  • 6 Mayer K, Bernlochner I, Braun S. , et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol 2014; 64 (09) 863-871
  • 7 Voora D, Cyr D, Lucas J. , et al. Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol 2013; 62 (14) 1267-1276
  • 8 Floyd CN, Goodman T, Becker S. , et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. Br J Clin Pharmacol 2014; 78 (02) 320-328
  • 9 Massimi I, Alemanno L, Guarino ML. , et al. MiR-21 role in aspirin-dependent PPARα and multidrug resistance protein 4 upregulation. Res Pract Thromb Haemost 2018; 2 (03) 596-606
  • 10 La Rosa G, Biasucci LM, Mandolini C. , et al. Platelet miRNA-26b down-regulates multidrug resistance protein 4 in patients on chronic aspirin treatment. J Cardiovasc Med (Hagerstown) 2018; 19 (10) 611-613
  • 11 Massimi I, Guerriero R, Lotti LV. , et al. Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets. Br J Clin Pharmacol 2014; 78 (06) 1343-1353
  • 12 Massimi I, Lotti LV, Temperilli F. , et al. Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment. Thromb Haemost 2016; 116 (06) 1100-1110
  • 13 Alemanno L, Massimi I, Klaus V. , et al. Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity. Thromb Haemost 2018; 118 (03) 490-501
  • 14 Tacconelli S, Dovizio M, Di Francesco L. , et al. Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. Clin Pharmacol Ther 2018; 104 (01) 111-119
  • 15 Lowenstern A, Storey RF, Neely M. , et al; PLATO Investigators. Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. J Thromb Thrombolysis 2017; 44 (02) 145-153
  • 16 Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273 (04) 2024-2029
  • 17 Savi P, Beauverger P, Labouret C. , et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422 (03) 291-295
  • 18 Santilli F, Rocca B, De Cristofaro R. , et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 2009; 53 (08) 667-677
  • 19 Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103 (03) 858-866
  • 20 Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273 (04) 2030-2034
  • 21 Greenberg SM, Rosenthal DS, Greeley TA, Tantravahi R, Handin RI. Characterization of a new megakaryocytic cell line: the Dami cell. Blood 1988; 72 (06) 1968-1977
  • 22 Sawabe Y, Shimamoto C, Sakai A. , et al. Peroxisome proliferation activation receptor alpha modulation of Ca2+-regulated exocytosis via arachidonic acid in guinea-pig antral mucous cells. Exp Physiol 2010; 95 (08) 858-868
  • 23 Guerriero R, Testa U, Gabbianelli M. , et al. Unilineage megakaryocytic proliferation and differentiation of purified hematopoietic progenitors in serum-free liquid culture. Blood 1995; 86 (10) 3725-3736
  • 24 Guerriero R, Mattia G, Testa U. , et al. Stromal cell-derived factor 1alpha increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. Blood 2001; 97 (09) 2587-2595
  • 25 Pulcinelli FM, Gresele P, Bonuglia M, Gazzaniga PP. Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. Biochem Pharmacol 1998; 56 (11) 1481-1484
  • 26 Temperilli F, Di Franco M, Massimi I. , et al. Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and multidrug resistance protein 4 expression in human platelets. Vascul Pharmacol 2016; 76: 11-17
  • 27 Lindemann SW, Yost CC, Denis MM, McIntyre TM, Weyrich AS, Zimmerman GA. Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs. Proc Natl Acad Sci U S A 2004; 101 (18) 7076-7081
  • 28 Massimi I, Ciuffetta A, Temperilli F. , et al. Multidrug resistance protein-4 influences aspirin toxicity in human cell line. Mediators Inflamm 2015; 2015: 607957
  • 29 Temperilli F, Rina A, Massimi I. , et al. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment. Platelets 2015; 26 (08) 783-787
  • 30 Elliott GR, Lauwen AP, Bonta IL. Prostaglandin E2 inhibits and indomethacin and aspirin enhance, A23187-stimulated leukotriene B4 synthesis by rat peritoneal macrophages. Br J Pharmacol 1989; 96 (02) 265-270
  • 31 Patel D, Roy A, Kundu M. , et al. Aspirin binds to PPARα to stimulate hippocampal plasticity and protect memory. Proc Natl Acad Sci U S A 2018; 115 (31) E7408-E7417
  • 32 Hu L, Chang L, Zhang Y. , et al. Platelets express activated P2Y12 receptor in patients with diabetes mellitus. Circulation 2017; 136 (09) 817-833
  • 33 Hechler B, Zhang Y, Eckly A, Cazenave JP, Gachet C, Ravid K. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. J Thromb Haemost 2003; 1 (01) 155-163
  • 34 FitzGerald GA, Oates JA, Hawiger J. , et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71 (03) 676-688
  • 35 Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43 (06) 979-984
  • 36 Vallet CM, Marquez B, Nhiri N. , et al. Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin. Toxicology 2011; 290 (2–3): 178-186